# **EVALUATION FORM**

Grand Rounds in Oncology:

How the Experts Treat Cancer Module 4 (Gastrointestinal Stromal Tumors)

**Release Date: January 1, 2012** 

The City of Hope respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. *You must complete this evaluation form and the posttest to receive a CME credit certificate.* 

#### **Please answer the following questions by circling the appropriate rating:**

5 = Outstanding	4 = Good	3 = Satisfactory	2 = Fair	1 = Poor					
	-	ies Met the Identified	-						
1 0 1	v	ucational activity, partie	•						
Compare and cont	rast different su	rgical, chemotherapy an	nd biologic age	ent combinations in the					
treatment of rescen	ctable, unresecta	ble, metastatic, or recur	rrent GIST		5	4	. 3	2	1
• Assess treatment options for and ongoing clinical trials of targeted agents in GIST 5					; 4	3	2	1	
Apply best practice	e strategies in di	iagnostic, surgical, syste	emic, and targ	eted therapies in the					
management of pa	tients with GIS	Г			5	4	. 3	2	1
• Evaluate the evolv	ing therapeutic	strategies in the treatme	ent of GIST		5	; 4	3	2	1
Overall Effectivene	ss of the Acti	vity							
• Was timely and wi	ll influence how	/ I practice			5	; 4	3	2	1
• Will assist me in in	nproving patien	it care			5	; 4	3	2	1
• Fulfilled my educa	tional needs				5	; 4	3	2	1
Avoided commerce	ial bias or influe	ence			5	; 4	3	2	1
Impact of the Activi	ity								
The information prese	ented:								
(check all that apply)									
C Reinforced my curr	*			prove my practice/patient					
Provided new ideas	or information	I expect to use	Enhance	ed my current knowledge	base				

Will the information presented cause you to make any changes in your practice?

□ Yes □ No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

How committed are you to making these changes?							
(Very committed)	5	4	3	2	1	(Not at all committed)	

### **Future Activities**

Do you feel future activities on this subject matter are necessary and/or important to your practice?

□ Yes □ No

## Page 2 EVALUATION FORM

Grand Rounds in Oncology: How the Experts Treat Cancer Module 4 (Gastrointestinal Stromal Tumors)

Please list any other topics that would be of interest to you for future educational activities:

#### Follow-up

As part of our ongoing continuous quality improvement effort, we conduct post-activity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

Yes, I would be interested in participating in a follow-up survey
No, I'm not interested in participating in a follow-up survey

Additional comments about this activity:

### **Request for Credit**

If you wish to receive acknowledgement of participation for this activity, please complete the posttest by selecting the best answer to each question. Complete this evaluation verification of participation and submit by email to **CME@coh.org** by clicking on the link below the posttest; or mail to **City of Hope Office of Continuing Medical Education**, **1500 East Duarte Road, Duarte, CA 91010**; or fax to **626-301-8939**.

Name		Degree	
Organization			
Address			
City, State, Zip			
Telephone	Fax	E-Mail	

I certify my actual time spent to complete this educational activity to be:

□ I participated in the activity *How the Experts Treat Cancer Module 4 (Gastrointestinal Stromal Tumors)* and claim 1.0 *AMA PRA Category 1 Credits*<sup>TM</sup>.

Signature \_\_\_\_\_ Date \_\_\_\_\_

#### **Post-test Answer Form**

1	2	3	4

## **CME POSTTEST**

## Grand Rounds in Oncology: How the Experts Treat Cancer Module 4 (Gastrointestinal Stromal Tumors)

- 1. Imatinib mesylate (Gleevee inhibits which tyrosine kinases linked to GIST oncogenesis:
  - A. c-Kit
  - B. PDGFR-β
  - C. Bcr-Ab1
  - D. PDGFR-a
  - E. Both A and D
- 2. If a patient with metastatic GIST demonstrates progression on imatinib 400 mg/day, you should:
  - A. Discontinue imatinib immediately and begin sorafenib.
  - B. Discontinue imatinib immediately and begin dasatinib.
  - C. Escalate dose of imatinib to 400 mg twice daily.
  - D. Discontinue imatinib immediately and begin sunitinib.

- 3. The surgical management of GIST tumors is different from gastric adenocarcinoma. Which one of the following is recommended for surgical excision of gastric GIST tumors? (There is only one correct answer.)
  - A. Wide surgical margins
  - B. Lymphadenectomy
  - C. Anatomic resection
  - D. Careful handling of tumor
- 4. Which of the following is not a symptom typical of GIST tumors? (There is only one correct answer.)
  - A. Bleeding
  - B. Jaundice
  - C. Obstruction
  - D. Palpable mass